Myrio Therapeutics announced it has developed binders in which both affinity and specificity can be increased simultaneously — a capability the company says rivals have not achieved. The advance reportedly comes from proprietary discovery and optimization workflows that improve target selectivity while enhancing binding strength, key parameters for biologics development including antibodies, peptides and alternative scaffolds. If reproducible at scale, this capability could reduce downstream optimization time, lower attrition in lead selection, and improve therapeutic index for targeted modalities. The biotech and partnering prospects will be the near-term yardstick for commercial and translational impact.